The anti-G17 immunogen will be tested on patients who have been treated unsuccessfully with 5-FU and irinotecan, the developers, Aphton, of Miami, Florida, USA, announced. The drug will be used in combination with irinotecan.
The anti-G17 immunogen is one of a family of "anti-hormone vaccines" being developed by the company.
It induces an antibody response against gastrin and other gastrin-related growth factors, and is claimed by its developers to be a unique, non-toxic, and innovative biological treatment.
The company said it is in the process of enlisting clinical trial sites and investigators in the USA, and also evaluating the possibilities of a similar trial in Europe.
Once it has evidence that terminally ill patients respond to the treatment, it plans to file for fast-track marketing approval in the USA.
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com